New drugs based on the modulation of adenosine receptors

PaloBiofarma is focused on developing innovative therapeutics that leverage the modulation of adenosinergic pathways, particularly through the use of selective adenosine receptor modulators. Their lead compound, PBF-680, is a potent oral adenosine A1 antagonist currently in Phase 2 clinical trials for the treatment of moderate-to-severe chronic obstructive pulmonary disease (COPD) and asthma. The company emphasizes a virtual drug design approach, utilizing their expertise in medicinal chemistry, in vitro pharmacology, and physico-chemical characterization to advance their drug candidates. They also collaborate with various contract research organizations (CROs), research centers, and universities to conduct necessary pharmacology and toxicology tests, ensuring comprehensive compound characterization.

PaloBiofarma's pipeline includes multiple compounds targeting diseases with high unmet medical needs, such as PBF-999, which has received Orphan Drug Designation for the treatment of Prader-Willi Syndrome. The company has successfully completed clinical trials demonstrating the safety and efficacy of PBF-680, showing significant improvements in lung function and reductions in blood eosinophils in previous studies. With a commitment to advancing their clinical development, PaloBiofarma aims to bring novel disease-modifying treatments closer to patients, addressing critical health challenges in respiratory diseases and beyond.

Spain

Palobiofarma S.L is a Spanish biotechnology company founded in 2006 by a group of scientists with experience in drug discovery in several pharmaceutical fields. The company is focused on developing innovative treatments for serious diseases and has been involved in various clinical trials for its most advanced compounds.

PaloBiofarma

Company Details